Estonie - estonien - Ravimiamet

organon n.v. - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 2tk; 50mcg 1annus 140annus 1tk

Estonie - estonien - Ravimiamet

zentiva k.s. - mometasoon - ninasprei, suspensioon - 50mcg 1mõõtannus 140mõõtannus 1tk; 50mcg 1mõõtannus 60mõõtannus 1tk

Estonie - estonien - Ravimiamet

mylan ireland limited - sunitiniib - kõvakapsel - 12,5mg 30tk

Estonie - estonien - Ravimiamet

mylan ireland limited - sunitiniib - kõvakapsel - 50mg 28tk

Estonie - estonien - Ravimiamet

cipla (eu) limited - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 1tk

Estonie - estonien - Ravimiamet

lex ano uab - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 3tk; 50mcg 1annus 140annus 1tk

Estonie - estonien - Ravimiamet

zentiva k.s. - sunitiniib - kõvakapsel - 12,5mg 28tk

Estonie - estonien - Ravimiamet

ideal trade links uab - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 1tk; 50mcg 1annus 140annus 3tk

Estonie - estonien - Ravimiamet

zentiva k.s. - sunitiniib - kõvakapsel - 50mg 28tk; 50mg 30tk

Union européenne - estonien - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.